PHARMA STARTUP MAY MOVE TO INDUSTRY HOTSPOT – AND THAT COULD MEAN MORE JOBS HERE
Dublin, Ohio (November 19, 2015) – A Central Ohio startup seeking potential new drugs within blooms of algae is seeking a pharmaceutical industry “star” as its next CEO, which might require moving the headquarters to an industry hotspot if the recruit desires it.
Continue ReadingBiosortia Announces Executive Leadership Change
Dublin, OH (November 12, 2015) – Biosortia Pharmaceuticals, a leader in discovering and co-developing potent novel bioactive compounds with a primary focus on drug discovery for cancer, infectious disease, and anti-inflammatory therapeutics, has announced today the appointment of Ross O. Youngs as interim CEO, effective immediately. Mr. Youngs succeeds Kurt Dieck who has resigned as President
Continue ReadingHollings Lab and Algaeventure Systems: Looking for Benefits in Harmful Algal Blooms
Author: Derek Parks | Dublin, Ohio (July 29, 2015) – The NOAA Ocean Service Hollings Marine Laboratory Cooperative Research and Development Agreement (CRADA), with Algaeventure Systems (dba Biosortia Pharmaceuticals), which was originally signed in 2012 and recently amended in 2014, has resulted in a wide array of successful outcomes for NOAA, and for its CRADA partners.
Continue ReadingELI LILLY RECOGNIZES BIOSORTIA PHARMACEUTICALS AS 2014 OIDD COLLABORATOR OF THE YEAR
Dublin, OH (Aril 8, 2015) – Eli Lilly has recognized Dublin, Ohio-based Biosortia Pharmaceuticals with the 2014 Open Innovation Drug Discovery (OIDD) Collaborator of the Year award. The Collaborator of the Year award is the result of the innovative results and progress created by Biosortia and Lilly’s OIDD team. Biosortia, a leader in discovering and co-develop
Continue ReadingBIOSORTIA CONDUCTS MICROALGAL CONSORTIA ASSESSMENTS THROUGHOUT THE U.S.
Dublin, OH (August 21, 2014) – Biosortia’s scout technologies make it possible to determine and prioritize the most optimal biomass harvesting sites as a source for new chemistry. Biosortia continues to conduct assessments throughout Ohio, Texas, Florida, Alabama, Kentucky, North Carolina, Michigan, and Mississippi. ### About Biosortia Pharmaceuticals – Biosortia Pharmaceuticals is a division of Algaeventure Systems (AVS).
Continue ReadingBIOSORTIA ADDS RENOWNED NATURAL PRODUCTS RESEARCHER HAIYIN HE, PH.D. AS VP OF RESEARCH
Dublin, OH (May 19, 2014) – The addition of Dr. He adds leadership and natural products drug discovery experience to Biosortia’s Science Team. Dr. He has more than 20 years of experience in pharmaceutical R&D, specializing in the discovery of drug leads from natural products and their semi-synthetic analogs in oncology, infectious disease, and other therapeutic
Continue ReadingBIOSORTIA ADDS RESEARCH AGREEMENTS WITH OHIO STATE UNIVERSITY, UNIVERSITY OF CALIFORNIA SANTA CRUZ, OLE MISS, AND PURDUE UNIVERSITY
Dublin, OH (April 2, 2014) – Biosortia is working with renowned drug discovery researchers at The Ohio State University, University of California Santa Cruz, Ole Miss, and Purdue University. Led by Chief Science Officer, Dr. Guy Carter, each research collaboration is strategically focused to complement Biosortia’s objective in providing Big Pharma with unique and highly portent
Continue ReadingBIOSORTIA ANNOUNCES DRUG DISCOVERY RESEARCH AGREEMENT WITH ASTRAZENECA
Dublin, OH (July 15, 2013) – Biosortia Pharmaceuticals announced today a research agreement with AstraZeneca to screen Biosortia’s library of unique natural products derived from aquatic microbial consortia for evaluation against AstraZeneca’s therapeutic targets. The agreement includes the evaluation of partially refined mixtures as well as individual compounds. The aquatic environment is a rich source of
Continue ReadingBiosortia Tapping into Nature to Fill Early Drug-Discovery Void
By Emily Mullin, (July 09, 2013) – At a time when most of the biopharma industry has focused its preclinical research on screening synthetic compounds for their drug potential, Biosortia Pharmaceuticals is going back to nature to find promising compounds at the early stage of discovery. Dublin, OH-based startup Biosortia is harvesting the communities, or consortia,
Continue ReadingBIOSORTIA LAUNCHES INFECTIOUS DISEASE DRUG DISCOVERY TRIAL
Dublin, OH (June 11, 2013) – Dr. Nancy Sawtell, a professor, and researcher at Cincinnati Children’s Hospital Medical Center, will be using technology developed by Biosortia Pharmaceuticals of Dublin, Ohio in collaboration to potentially discover new biologically active natural products for the treatment of infectious diseases. The drug discovery research is focused on the evaluation of
Continue Reading